This article describes an aspect of the progressive insertion of commercial interests into the relationship between patients and their clinicians, with particular reference to psychiatry. Treatment noncompliance, a long-standing problem for healthcare professionals, has lately drawn the attention of the pharmaceutical and allied industries as a site at which to improve return on investment (ROI). Newly founded corporate `compliance departments' and specialized consultancies that regard noncompliance as a form of marketing failure are seeking to rectify it with reinvigorated models and strategies. This intervention stands to impact patients' experience of illness as well as the participation of those formally (physicians, case managers, etc.) and informally (family, friends, etc.) involved in treatment. My analysis draws upon observation at compliance conferences to demonstrate the contrasting models of patient empowerment underlying the marketing vs. medical approaches. I propose a research agenda for measuring the effects of industry compliance programs.
Antonuccio, D.O., Danton, W.G., & McClanahan, T.M. (2003). Psychology in the prescription era: Building a firewall between marketing and science. American Psychologist, 58, 1028-1043.
2.
Applbaum, K. (2000). Marketing and commoditization. Social Analysis, 44(2), 106-128.
3.
Applbaum, K. (2004). The marketing era: From professional practice to global provisioning. New York: Routledge.
4.
Applbaum, K. (2006a). Educating for global mental health: The adoption of SSRIs in Japan. In A. Petryna, A. Lakoff, & A. Kleinman (Eds.), Global pharmaceuticals. Ethics, markets, practices (pp. 85-110). Durham, NC: Duke University Press.
5.
Applbaum, K. (2006b). Pharmaceutical marketing and the invention of the medical consumer. PLoS Medicine, 3(4), e189. DOI: 10.1371/journal.pmed.0030189 A.
6.
Applbaum, K. (in press). Corporate power and the creation of a psychopharmaceutical blockbuster. Culture, Medicine and Psychiatry.
7.
Awad, G. (2004). Antipsychotic medications: Compliance and attitudes towards treatment. Current Opinion in Psychiatry, 17(2), 75-80.
8.
Awad, A.G., & Voruganti, L.N.P. (2004) New antipsychotics, compliance, quality of life and subjective tolerability: Are patients better off?Canadian Journal of Psychiatry, 49, 297-302.
9.
`Big Pharma's Nurse Will See You Now': Drug companies are hiring RNs to educate patients - and boost marketing. (2006, June 12). BusinessWeek, pp. 77-78.
10.
Bissell, P., May, C.R., & Noyce, P.R. (2004). From compliance to concordance: Barriers to accomplishing a re-framed model of health care interactions. Social Science and Medicine, 58, 851-862.
11.
Conrad, P., & Leiter, V. (2004). Medicalization, markets and consumers. Journal of Health and Social Behavior, 45(Suppl.), 158-176.
12.
Deegan, P.E., & Drake, R.E. (2006). Shared decision-making and medication management in the recovery process. Psychiatric Services, 57(11), 1636-1639.
13.
Donohoe, G. (2006). Adherence to antipsychotic treatment in schizophrenia: What role does cognitive behavioral therapy play in improving outcomes? Disease Management and Health Outcomes, 14(4), 207-214.
14.
Drucker, P. (1973). Management: Tasks, responsibilities, practices . New York: Harper & Row.
15.
Estroff, S.E. (1981). Making it crazy: An ethnography of psychiatric clients in an American community. Berkeley: University of California Press.
16.
Granovetter, M. (1985). Economic action and social structure: The problem of embeddedness. American Journal of Sociology, 91(3), 481-510.
17.
Gray, R., Wykes, T., & Gournay, K. (2002). From compliance to concordance: A review of the literature on interventions to enhance compliance with antipsychotic medication . Journal of Psychiatric and Mental Health Nursing, 9, 277-284.
18.
Greene, J. (2007). Prescribing by numbers. Baltimore , MD: Johns Hopkins University Press.
19.
Haynes, R.B., Taylor, D.W., & Sachett, D.L. (1979). Compliance in health care. Baltimore, MD: Johns Hopkins University Press.
20.
Healy, D. (2003). Let them eat Prozac. Toronto, ON: James Lorimer & Co.
21.
Healy, D. (2004). Shaping the intimate: Influences on the experience of everyday nerves. Social Studies of Science, 34, 219-245.
22.
Hopfield, J., Linden, R.M., & Tevelow, B.J. (2006). Getting patients to take their medicine. The McKinsey Quarterly, 4(1-2), 14-15.
23.
Jenkins, J.H. (2004). Schizophrenia as a paradigm case for understanding fundamental human processes. In J. H. Jenkins & R. J. Barrett (Eds.), Schizophrenia, culture and subjectivity (pp. 29-61). Cambridge: Cambridge University Press.
24.
Jenkins, J. H., & Barrett, R. J. (Eds.). (2004). Schizophrenia, culture and subjectivity. Cambridge: Cambridge University Press.
25.
Joukamaa, M., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., et al. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188, 122-127.
26.
Kemp, R., Hayward, P., & David, A. (1997). Compliance therapy manual. London: Bethlem and Maudsley NHS Trust.
27.
Kleinman, A. (2006). What really matters. Oxford : Oxford University Press.
28.
Lauriello, J., Lenroot, R., & Bustillo, J.R. (2003). Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia. Psychiatric Clinics of North America, 26(1), 191-211.
29.
Longhofer, J., Floersch, J., & Jenkins, J.H. (2003). Medication effect interpretation and the social grid of management. Social Work in Mental Health, 1(4), 71-89.
30.
Medawar, C., & Hardon, A. (2004). Medicines out of control? Antidepressants and the conspiracy of goodwill. Amsterdam: Aksant Academic Publishers.
31.
Moynihan, R. (2004). The intangible magic of celebrity marketing. PLoS Medicine, 1, e42. DOI: 10.1371/journal.pmed.0010042.
32.
Nichol, M.B., Venturini, F., & Sung, J.C. (1999). A critical evaluation of the methodology of the literature on medication compliance. Annals of Pharmacotherapy , 33(5), 531-540.
33.
Patel, M.X., & David, A.S. (2005). Why aren't depot antipsychotics prescribed more often and what can be done about it? Advances in Psychiatric Treatment, 11, 203-213.
34.
Perkins, R., & Repper, J. (1998). Dilemmas in community mental health practice: Choice or control. Oxford: Radcliffe Medical Press.
35.
Phillips, C.B. (2006). Medicine goes to school: Teachers as sickness brokers for ADHD. PLoS Medicine, 3(4), e182. DOI: 10.1371/journal.pmed.0030182.
36.
Porter, R. (2002). Madness: A brief history. Oxford: Oxford University Press.
37.
Rhodes, L. (1991). Emptying beds: The work of an emergency psychiatric unit. Berkeley: University of California Press.
38.
Rivers, W.H.R. (1924). Medicine, magic and religion. London: Kegan Paul, Trench and Trubner.
39.
Safer, D.J. (2002). Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. Journal of Nervous Mental Disorders, 190, 583-592.
40.
Seale, C., Chaplin, R., Lelliott, P., & Quirk, A. (2006). Sharing decisions in consultations involving anti-psychotic medication: A qualitative study of psychiatrists' experiences. Social Science and Medicine, 62(11), 2861-2873.
41.
Shaw, G.B. (1963). Preface on doctors: Bernard Shaw complete plays with prefaces, Volume I. New York: Dodd, Mead & Company.
42.
Smardon, R. (2008). `I'd rather not take Prozac': Stigma and commodification in antidepressant consumer narratives. Health, 12(1), 67-86.
43.
Trostle, J.A. (1988). Medical compliance as ideology. Social Science and Medicine, 27(12), 1299-1308.
44.
Zygmunt, A., Olfson, M., & Boyer, C.A. (2002) Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry, 159, 1653-1664.
